Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC1
- Development stage
- Unknown
- Lead developer
- The Greater Cannabis Company
- Modality
- Small Molecules
- Administration
- Oral, Sublingual, Inhalation, Topical, Rectal
01
Overview
PC1 is a proprietary cannabinoid small molecule developed by The Greater Cannabis Company (GCANRx) for the treatment of Autism Spectrum Disorder (ASD) and other neuropsychiatric illnesses. It is designed to be used as part of a combination therapy alongside cannabidiol (CBD) and another proprietary compound, PC2. This triple-combination approach is intended to improve core ASD symptoms, including behavioral outbursts, communication, and anxiety, while maintaining a favorable safety profile. The combination therapy has received approval for a Phase 2 clinical trial to evaluate its safety and efficacy in patients with ASD.
- Other names
- Proprietary Compound 1
Beyond the preview
Go deeper on PC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC1.